Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Ovarian Neoplasms 15Fallopian Tube Neoplasms 13Lung Neoplasms 11Melanoma 8Colorectal Neoplasms 8Glioblastoma 7Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Brain Neoplasms 4Rectal Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Uveal Melanoma 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Oligodendroglioma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, B-Cell 2Lymphoma 2

Interventions

Rituximab 45Cyclophosphamide 34Doxorubicin 16fludarabine 14Prednisone 14Vincristine 13Etoposide 13ibrutinib 10Mycophenolic Acid 8Bortezomib 8Magnetic Resonance Spectroscopy 7Lenalidomide 7Cytarabine 7pembrolizumab 6Immunotherapy, Adoptive 6polatuzumab vedotin 5fludarabine phosphate 5Whole-Body Irradiation 5Vorinostat 5Tacrolimus 5Specimen Handling 5CT-P10 5obinutuzumab 4ibritumomab tiuxetan 4Nivolumab 4Ifosfamide 4Carmustine 4Carboplatin 4Antilymphocyte Serum 4tafasitamab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell × Disulfides × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
37 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡